UK markets closed

Compugen Ltd. (CGEN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.5800+0.0400 (+1.57%)
At close: 04:00PM EDT
2.5900 +0.01 (+0.39%)
After hours: 05:32PM EDT

Compugen Ltd.

Azrieli Center
Building D 26 Harokmim Street
Holon 5885849
Israel
972 3 765 8585
https://cgen.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees68

Key executives

NameTitlePayExercisedYear born
Dr. Anat Cohen-Dayag Ph.D.CEO, President & Director796.52kN/A1967
Dr. Zurit Levine Ph.D.Senior Vice President of Technology Innovation345.7kN/A1968
Dr. Pierre Ferre Ph.D.Vice President of Preclinical Development415.1kN/A1977
Mr. Alberto SessaChief Financial OfficerN/AN/A1962
Dr. Eran Ophir Ph.D.Chief Scientific OfficerN/AN/A1978
Ms. Yvonne NaughtonHead of Investor Relations & Corporate CommunicationsN/AN/AN/A
Mr. Eran Ben DorGeneral Counsel & Corporate SecretaryN/AN/AN/A
Ms. Dorit AmitayVice President of Human ResourcesN/AN/A1968
Dr. Yaron Turpaz M.B.A., Ph.D.Senior VP & Senior Advisor of Data and Informatics SolutionsN/AN/A1971
Rivka SchwartzVice President Research and DiscoveryN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Corporate governance

Compugen Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.